Ziprasidone in the short-term treatment of patients with schizoaffective disorder: Results from two double-blind, placebo-controlled, multicenter studies

Journal of Clinical Psychopharmacology

Volumn 21, Issue 1, 2001, Pages 27-35

  Keck Jr , Paul E ^a   Reeves, Karen R ^b   Harrigan, Edmund P ^b  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; ZIPRASIDONE;

ADULT; AKATHISIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INSOMNIA; MALE; MOTOR DYSFUNCTION; MULTICENTER STUDY; PAIN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPIRATORY TRACT DISEASE; RHINITIS; SCHIZOIDISM; SOMNOLENCE; TREMOR; VERTIGO; XEROSTOMIA;

ADOLESCENT; ADULT; ANTIPSYCHOTIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; MOVEMENT DISORDERS; PIPERAZINES; PSYCHOTIC DISORDERS; THIAZOLES; TREATMENT OUTCOME;

EID: 0035145340     PISSN: 02710749     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004714-200102000-00007     Document Type: Article

References (47)

1. An 8-year follow-up of patients with DSM-III-R psychotic depression, schizoaffective disorder and schizophrenia
2. Long-term course and outcome in schizoaffective disorder
3. Pharmacologic treatment of schizoaffective disorder
4. New developments in the pharmacologic treatment of schizoaffective disorder
5. Comparative effects of lithium and chlorpromazine in the treatment of acute manic states
6. A controlled study of lithium vs. chlorpromazine in acute schizophrenics
7. A comparison of lithium carbonate and chlorpromazine in the treatment of excited schizoaffectives
8. A placebo-controlled study of lithium combined with neuroleptics in chronic schizophrenic patients
9. Trials of lithium, chlorpromazine and amitriptyline in schizoaffective patients
10. Antipsychotic effects of lithium in schizophrenia
11. Combination of lithium carbonate and haloperidol in schizoaffective disorder
12. Lithium in chronic schizophrenia
13. Treatment of secondary depression in schizophrenia: A double-blind, placebo-controlled study of amitriptyline added to perphenazine
14. Synergism of combined lithium-neuroleptic therapy: A double-blind, placebo-controlled case study
15. Lithium combined with neuroleptics in chronic schizophrenic and schizoaffective patients
16. Lithium and chlorpromazine in psychotic inpatients
17. Treatment of schizoaffective disorder
18. The new antipsychotics and their therapeutic potential
19. The role of serotonin in schizophrenia
20. Clozapine in the treatment of psychotic mood disorders, schizoaffective disorder, and schizophrenia
21. The European experience with use of clozapine
22. Clozapine therapy in refractory affective disorders: Polarity predicts response in long-term follow-up
23. Risperidone in the treatment of disorders with combined psychotic and depressive syndrome - A functional approach
24. Clinical predictors of acute risperidone response in schizophrenia, schizoaffective disorder and psychotic mood disorders
25. Antidepressant activity and mania associated with risperidone treatment of schizoaffective disorder
26. Olanzapine versus haloperidol in the treatment of schizoaffective disorder: Acute and long-term therapy
27. Ziprasidone (CP-88,059). Preclinical pharmacology review
28. 3-Benzisothiazolylpiperaine derivatives as potential atypical antipsychotic agents
29. Ziprasidone hydrochloride
30. A new antipsychotic with combined dopamine and serotonin receptor antagonist activity
31. Preclinical pharmacology of new atypical antipsychotics in late stage development
32. Tricyclics and tetracyclics
33. Hypersensitive serotonergic receptors involved in clinical depression - A theory
34. 3H]spiroperidol by chronic treatment with the antidepressant amitriptyline
35. Postsynaptic serotonergic blockade following chronic antidepressive treatment with trazodone in an animal model of depression
36. Mixed depression and anxiety: Serotonin 1A receptors as a common pharmacologic link
37. Ziprasidone 20 and 60 mg twice daily in the acute exacerbation of schizophrenia and schizoaffective disorder: A 4-week placebo-controlled trial
38. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: A 6-week placebo-controlled trial
39. Anchoring the BPRS to improve reliability
40. Positive and negative syndromes in schizophrenia: Assessment and research
41. Clinical global impression improvement scale
42. Clinical Global Impression Severity Scale
43. A new depression scale designed to be sensitive to change
44. A rating scale for extrapyramidal side effects
45. A rating scale for drug-induced akathisia
46. Abnormal involuntary movement scale